Clay Siegall is a skilled biotechnology expert who is impacting lives of cancer patients all over the world. Clay is the profound founder of Seattle Genetics, which is a biotechnology established in the year 1998 and it has since instituted many cancer therapies. The company made debut in the cancer treatment industry when it created Adcetris, which is already being utilized in the market. In a recent report, the Adcetris drug has successfully managed to cure over 15,000 lymphoma cases in the world.
Currently, Clay Siegall serves as both the president and chief executive officer at Seattle Genetics. He additionally serves as the chair to the board of directors. Under his leadership tenure, Seattle Genetics has been working hard to establish an extensive portfolio, which could address preclinical and clinical products that could treat the different forms of cancers as well as other autoimmune illnesses affecting today’s people.
Seattle Genetics is presently regarded as one of the leaders in the United States’ antibody technologies, in particular in the division of antibody-drug conjugate. The firm’s success is attributable to the skills and experience of their CEO and president, Clay Siegall. The renowned biotechnology expert has also been pioneering the capital raising procedures of the Seattle Genetics firm. In a recent report, Clay Siegall is considered to have aided the company in raising more than hundred million in both public and private financing
The Clay Siegall-raised capital will be utilized in developing safer and better drugs for treating the prevalent cancers affecting today’s society. According to Siegall, Seattle Genetics will begin introducing treatment drugs for breast cancer soon. The firm has additionally released a report, which stated that it aims at adding the number of its workforce for facilitating the development of new drugs. Before he founded Seattle Genetics, Clay Siegall was deeply into the biotechnology sector. He once worked with the renowned Bristol-Myers, which is among the most famous firms in the US. He has additionally served at the National Cancer Institute. Through his skills and experience in the sector, Clay Siegall has been of positive impact in every position he has held in the various entities he has worked with. Clay Siegall is also an outside director of the Mirna Therapeutics board of directors.